Navigating UnitedHealthcare Skyrizi Prior Authorization

Successfully managing UnitedHealthcare Skyrizi prior authorization is critical for patient access to this IL-23 inhibitor. Klivira provides a clear pathway to navigate UHC's specific requirements.

Revenue cycle directors and prior authorization coordinators face complex workflows for high-cost specialty medications like Skyrizi (risankizumab). Understanding UnitedHealthcare's specific channels, criteria, and operational nuances is essential to minimize delays and denials for patients requiring treatment for conditions such as plaque psoriasis, psoriatic arthritis, or Crohn's disease.

Understanding Skyrizi (Risankizumab) and its Indications

Skyrizi, known generically as risankizumab, is an IL-23 inhibitor developed by AbbVie. This biologic medication is commonly prescribed for chronic inflammatory conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's disease. Due to its classification and cost, Skyrizi universally requires prior authorization from payers like UnitedHealthcare.

UnitedHealthcare's Prior Authorization Process for Specialty Drugs

For specialty medications such as Skyrizi, UnitedHealthcare's prior authorization process is often managed through OptumRx, its owned PBM, or via the medical benefit depending on the specific line of business and benefit design. Providers must verify whether Skyrizi falls under the pharmacy or medical benefit for each member, as this dictates the submission channel and applicable policies. This split is therapeutic-category specific and may include site-of-care policies.

Key Submission Channels for Skyrizi Prior Authorization with UnitedHealthcare

UnitedHealthcare offers several pathways for submitting prior authorization requests for Skyrizi. For medical-benefit PAs across commercial, Medicare Advantage, and Community Plan lines, the UnitedHealthcare Provider Portal at uhcprovider.com is the primary channel. Pharmacy-benefit PAs, typically managed by OptumRx, can be submitted through OptumRx's provider PA system or via ePA partners like CoverMyMeds and Surescripts for prescriber-initiated workflows. X12 278 transactions are also accepted via clearinghouses for medical-benefit procedures.

Accessing UnitedHealthcare's Medical Necessity Criteria for Skyrizi

UnitedHealthcare publishes its medical-necessity criteria and coverage rules through its public Medical Policy Library. This resource is essential for understanding the clinical requirements for Skyrizi approval, including specific diagnostic criteria, step therapy requirements, and treatment duration. Reviewing the applicable policy number and effective date is crucial for preparing a complete submission.

Common Denial Reasons and Appeal Pathways for Skyrizi with UHC

Denials for Skyrizi prior authorizations with UnitedHealthcare often stem from insufficient clinical documentation, failure to meet medical necessity criteria outlined in UHC's policies (e.g., inadequate trial of preferred agents, off-label use without compendium support), or site-of-service mismatches. Should a denial occur, UHC documents the appeal pathway in its provider administrative guides, with distinct processes for commercial, Medicare Advantage, and Medicaid lines. Peer-to-peer reviews are available for clinical denials.

Klivira's Role in Streamlining UnitedHealthcare Skyrizi Prior Authorization

Klivira integrates directly with EMRs and payer portals, automating the complex steps involved in obtaining UnitedHealthcare Skyrizi prior authorization. Our platform helps identify the correct submission channel (medical benefit via uhcprovider.com or pharmacy benefit via OptumRx/ePA partners), surfaces relevant medical policies, and streamlines documentation submission to improve turnaround times and reduce administrative burden for your team.

Frequently asked questions

Which UnitedHealthcare entity handles Skyrizi prior authorizations?

For Skyrizi, the prior authorization process depends on whether it falls under the medical or pharmacy benefit. OptumRx, UnitedHealth Group's PBM, typically handles pharmacy-benefit specialty drug PAs. Medical-benefit PAs are processed through the UnitedHealthcare Provider Portal at uhcprovider.com. It is critical to verify the member's specific benefit design.

Where can I find UnitedHealthcare's medical necessity criteria for Skyrizi?

UnitedHealthcare publishes its medical necessity criteria and coverage rules in its public Medical Policy Library. Providers should search this library for the specific policy related to risankizumab or the relevant therapeutic class to understand clinical requirements, step therapy, and other coverage guidelines.

Does UnitedHealthcare accept electronic prior authorizations (ePA) for Skyrizi?

Yes, UnitedHealthcare supports ePA. For pharmacy-benefit Skyrizi, ePA can be submitted via OptumRx's systems or through ePA partners like CoverMyMeds and Surescripts. For medical-benefit PAs, the UHC Provider Portal is a primary electronic submission channel, and X12 278 transactions are also accepted via clearinghouses.

What are common reasons for a Skyrizi prior authorization denial from UnitedHealthcare?

Common denial reasons include insufficient clinical documentation, failure to meet medical necessity criteria outlined in UHC's policies (e.g., lack of documented prior therapies or specific disease activity), off-label use without compendium support, or issues related to the proposed site of service for administration. Reviewing the specific denial reason code is essential for appeals.

How do turnaround times for Skyrizi prior authorizations with UnitedHealthcare vary?

Turnaround times for UnitedHealthcare prior authorizations are subject to state-mandated minimums for commercial plans and specific service-level targets published by UHC on its provider prior-auth landing page. For Medicare Advantage and Medicaid (Community Plan) lines, CMS-0057-F mandates 72-hour standard and 24-hour expedited decisions, with phased compliance through 2027.